Showing 1 - 10 of 1,038
This paper analyzes the relationship between postmarketing promotional activity and reporting of adverse drug events by modeling the interaction between a welfare maximizing regulator (the FDA) and a profit maximizing firm. In our analysis demand is sensitive to both promotion and regulatory...
Persistent link: https://www.econbiz.de/10012464015
and consequences of innovation, we have concentrated on the products we have rated as innovative. Section I explains our … sample. In Section II we discuss trends in the rate of drug innovation and the factors influencing those trends. Section III …
Persistent link: https://www.econbiz.de/10012479025
This paper studies how insurance coverage policies affect incentives for pharmaceutical innovation. In the United …
Persistent link: https://www.econbiz.de/10012481418
Innovation policy involves trading off monopoly output and pricing in the short run in exchange for incentives for …
Persistent link: https://www.econbiz.de/10012481677
pharmaceutical patent protection alone does not stimulate domestic innovation, as estimated by the US patent awards (both raw counts … innovation acceleration and technology transfer, conditional upon certain country variables. In particular, the interaction …Research on the effects of patent protection on innovation and technology transfer in the cross-country pharmaceutical …
Persistent link: https://www.econbiz.de/10012462357
We examine the impact of pharmaceutical innovation on the longevity of Australians during the period 1995-2003. Due to …
Persistent link: https://www.econbiz.de/10012464638
This paper investigates the effect of (potential) market size on entry of new drugs and pharmaceutical innovation …
Persistent link: https://www.econbiz.de/10012468658
Pharmaceutical innovation policy involves managing a tradeoff between high prices for new products in the short … pharmaceuticals, suggesting low(er) price markets may have different dynamics with respect to innovation policy …
Persistent link: https://www.econbiz.de/10012533304
from pharmaceutical innovation. Extending previous studies of the welfare benefits from innovation (Trajtenberg, 1990 …
Persistent link: https://www.econbiz.de/10012471921
We perform an econometric investigation of the contribution of pharmaceutical innovation to mortality reduction and … pharmaceutical innovation, there would have been no increase and perhaps even a small decrease in mean age at death, and that new … drugs have increased life expectancy, and lifetime income, by about 0.75-1.0% per annum. The drug innovation measures are …
Persistent link: https://www.econbiz.de/10012472240